Twenty years of unnecessary suffering.
In November 2025, the FDA reversed decades of misleading warnings about hormone replacement therapy, acknowledging that tens of millions of women had been denied safe, effective care. At Raden Wellness, we help women reclaim what was taken from them.
FDA REVERSAL 2025
A historic correction, and a long overdue apology to women everywhere.
The FDA removed misleading black box warnings on hormone replacement therapy after acknowledging that the original Women’s Health Initiative enrolled women averaging 63 years old—over a decade past menopause—using a hormone formulation no longer in common use. As FDA Commissioner Marty Makary stated, women had been denied “life-changing and long-term health benefits” because of a distortion of risk. The new guidance recommends initiating HRT within 10 years of menopause onset or before age 60.
Menopause is a universal female life stage linked to more than 70% of the leading age-related diseases—including cardiovascular disease, osteoporosis, and cognitive decline. Yet less than 1% of scientific studies on aging include menopause-related variables, and the NIH allocated just $56 million of its $47.7 billion 2023 budget to menopause research. The consequence has been generations of women managed symptomatically, rather than treated at the biological root.
Hormone replacement therapy, when properly matched to the individual and initiated at the right time, is not a risk. It is a restoration—of energy, cognitive clarity, emotional resilience, cardiovascular protection, and bone density. The question was never whether women should have access to it. The question was always whether their physicians were asking the right questions.
"When I meet a new patient, the first conversation isn't about prescribing anything. It's about unlearning, setting aside decades of fear built on flawed science and helping her understand what her body actually needs."
RADEN MEDICAL TEAM
The Reach of Estrogen, Progesterone & Testosterone
These are not reproductive hormones that become irrelevant after a woman’s childbearing years. They are systemic regulators of brain function, vascular health, cellular metabolism, and longevity, and their decline has measurable consequences across every major organ system.
Brain & Cognition
Brain & Cognition
Cardiovascular & Bone Health
Cardiovascular & Bone Health
Energy & Body Composition
Energy & Body Composition
Mood & Emotional Resilience
Mood & Emotional Resilience
Libido & Sexual Vitality
Libido & Sexual Vitality
Neuroprotection & Longevity
Neuroprotection & Longevity
Not All Hormones Are the Same
The original WHI warnings pertained to synthetic hormone formulations. The fear they generated was applied indiscriminately to all hormone therapy, including bioidentical hormones, which are molecularly identical to those your body produces. These are not the same compounds, and conflating them has caused enormous harm.
SYNTHETIC HORMONES
Chemically altered; does not fully match your body’s own hormones
- TSH: A starting signal, not an endpoint. Interpreted alongside the full panel and within functional reference ranges.
- Reverse T3 (rT3): A marker of stress-driven thyroid suppression. Elevated rT3 blocks active T3 at the receptor level and signals systemic inflammation.
- Cortisol (AM & Diurnal): Evaluates the adrenal-thyroid axis and identifies stress-driven hormonal interference in T3 conversion.
BIOIDENTICAL HORMONES
Molecularly identical to hormones naturally produced by the human body
- Free T4 & Free T3: The inactive and active forms of thyroid hormone. Free T3 reflects what is actually available for cellular use.
- TPO & Anti-Thyroglobulin: Antibodies Autoimmune markers that identify immune-mediated thyroid destruction—often years before TSH becomes abnormal.
- Viral & Inflammatory Markers: Including EBV reactivation titers, CRP, and cytokine patterns that may be driving or perpetuating autoimmune thyroid disease.
Hormone Balance Begins in the Gut
Prescribing hormones without first assessing the gut microbiome is like refilling a leaking tank. The gut actively regulates estrogen metabolism through an enzyme called beta-glucuronidase, produced by bacteria in states of dysbiosis. When elevated, this enzyme deconjugates estrogens the liver has packaged for elimination—releasing them back into circulation and producing estrogen excess that no amount of dose adjustment will resolve.
This is why our hormone evaluation always begins with a comprehensive gut assessment. Achieving true hormonal balance requires that the metabolic pathways responsible for processing those hormones are functioning properly first.
Our Gut-First Evaluation
- Comprehensive Stool Analysis: Evaluates microbial diversity, dysbiosis patterns, and beta-glucuronidase activity—the enzyme directly responsible for estrogen recirculation.
- Serum Estrogen Metabolites: Measures circulating estradiol and estrone to identify whether elevated levels are driven by recirculation rather than endogenous production or therapy.
- Digestive Function Assessment: Identifies hypochlorhydria, impaired enzyme signaling, and other disruptions that set the stage for dysbiosis and downstream hormonal imbalance
- Targeted Microbiome Restoration: When indicated, antimicrobial botanicals, calcium D-glucarate, and dietary modification address the microbial root of estrogen excess before hormones are prescribed.
Testosterone Is Not a Male Hormone
Testosterone is the most abundant active sex steroid in women across the lifespan. Despite more than 80 years of clinical use and robust safety data, there are zero FDA-approved testosterone therapies for women—while more than 30 exist for men. That regulatory gap has left countless women without access to one of the most powerful tools available for mood, energy, cognition, bone density, and sexual vitality.
When used in physiological doses, testosterone in women does not cause masculinization or virilization. What it does is restore the hormonal substrate underlying confidence, cognitive sharpness, and physical resilience. Emerging evidence also suggests meaningful cardioprotective benefits, with one large analysis finding nearly a 50% reduction in major cardiac events in women aged 18–55, with no increased breast cancer risk.
of perimenopausal women on testosterone therapy reported improved mood at 4 months
reported enhanced cognitive function; all nine assessed domains showed statistically significant improvement
reduction in major adverse cardiac events in women aged 18–55 on testosterone therapy
FDA-approved testosterone therapies exist for women, despite decades of evidence supporting safety and efficacy
Schedule a consultation for a comprehensive women's hormone evaluation, one that begins with your biology, not a protocol.
Schedule a consultation to have your thyroid function evaluated with the depth and precision it requires.